Considering therapeutic antibodies

Science

Volumn 313, Issue 5785, 2006, Pages 308-309

  Vitetta, Ellen S ^a   Ghetie, Victor F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD28 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; T LYMPHOCYTE RECEPTOR; TGN 1412; MONOCLONAL ANTIBODY TGN1412;

ANTIBODY;

ANTIBODY PRODUCTION; COMA; DRUG DESIGN; DRUG SYNTHESIS; GANGRENE; HEART FAILURE; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; KIDNEY FAILURE; LIVER FAILURE; NONHUMAN; PAIN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; SIDE EFFECT; SWELLING; T LYMPHOCYTE ACTIVATION; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ARTICLE; CHEMISTRY; CLINICAL TRIAL; DRUG SCREENING; HALF LIFE TIME; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROTEIN ENGINEERING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES, ANTIBODY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; PROTEIN ENGINEERING; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 33746523114     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1130482     Document Type: Review

References (8)

1. E. Marshall, Science 311, 1685 (2006).
2. N. Beyersdorf, T. Hanke, T. Kerkau, T. Hunig, Ann. Rheum. Dis. 64 (suppl 4), 91 (2005).
3. R. Luhdler et al., J. Exp. Med. 197, 955 (2003).
4. O. H. Brekke, I. Sandlie, Nat. Rev. Drug Discov. 2, 52 (2003).
5. T. A. Waldmann, J. C. Morris, Adv. Immunol. 90, 83 (2006).
6. X. Liu, L. M. Pop, D. C. Roopenian, V. Ghetie, E. S. Vitetta, J. E. Smallshaw, Int. Immunopharmacol. 6, 791 (2006).
7. P. Holliger, P. J. Hudson, Nat. Biotechnol. 23, 1126 (2005).
8. We thank N. VanOers, J. Niederkorn, D. Farrar, N. Karandikar, J. Uhr, and H. W. Corley for their insightful discussion.